Epredia will add Mindpeak AI modules for pathology to its digital pathology portfolio, offering enhanced precision and speed in diagnostic image review
Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation, and Mindpeak, a leading provider of artificial intelligence (AI) solutions for clinical and research pathology, announced a distribution agreement to bring Mindpeak’s AI-based image recognition software to Epredia’s digital pathology customers in the European Union.
As cancer cases increase and diagnostic processes become more complex, pathology laboratories are under pressure to speed up processes and reduce costs. Mindpeak’s AI technology delivers instant, pixel-level analysis of digital images of tissue samples, enabling objective and reproducible assessments in breast cancer, lung cancer, gastrointestinal pathology, biomarker quantification and exploratory research studies. These tools are designed to reduce variability, support decision-making and improve workflow efficiency, all without requiring cloud connectivity, thereby offering data privacy and security for both clinical and research environments. Mindpeak’s AI portfolio includes a range of both CE Marked and research-use-only modules.
Also Read: Viz.ai Names Jallel Harrati as Chief Revenue Officer
Under the agreement, Epredia will offer Mindpeak’s AI software for clinical diagnostics, translational research, and pharmaceutical development. In the future, Epredia also intends to explore integration of Mindpeak’s AI solutions into the Epredia E1000 Dx Digital Pathology Solution workflow, which would enable a seamless workflow and streamlined data exchange through Epredia’s image management system. The E1000 Dx consists of a high-speed, automated, whole-slide imaging digital scanner with medical grade viewer and advanced image management and viewer software that allows review of up to 1,500 high-resolution digital images daily.
“Epredia is committed to providing the right tool at the right time to help pathology labs deliver accurate, efficient diagnoses of cancer, so patients can get the care they need,” said Steven Lynum, President of Epredia. “Our entire workflow of solutions, from stains to digital scanners, works together to create the high-quality tissue samples needed for diagnosis, and AI image recognition software has the potential to bring a new level of speed, accuracy, and reliability to that process.”
“Working with Epredia strengthens our shared mission to bring reliable, real-time AI support into the hands of pathologists everywhere,” said Felix Faber, Co-founder and CEO of Mindpeak. “Together we can help laboratories achieve faster, more consistent image interpretation and move closer to scalable, expert-directed cancer diagnostics.”
This agreement will expand Epredia’s portfolio of end-to-end pathology solutions that includes pathology consumables like slides and stains, instruments from tissue processors to cryostats, and advanced image management systems including AI-enabled tools.
Source: Businesswire
